A non-inferiority trial of cytisine versus varenicline for smoking cessation

  • Farrell, Michael P. (Primary Chief Investigator (PCI))
  • Courtney, Ryan James (Chief Investigator (CI))
  • Walker, Natalie (Chief Investigator (CI))
  • McRobbie, Hayden J. (Chief Investigator (CI))
  • Gartner, Coral (Chief Investigator (CI))
  • Siahpush, Mohammad (Chief Investigator (CI))
  • Petrie, Dennis (Chief Investigator (CI))
  • Paul, Christine Louise (Chief Investigator (CI))
  • Richmond, Robyn L (Chief Investigator (CI))
  • Ferguson, Stuart (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Tobacco smoking is a leading cause of preventable disease and death. Smoking rates are higher among disadvantaged Australians and facilitating smoking cessation in this group is a national health priority. A number of strategies can increase cessation success, but relatively few smokers use proven effective strategies on any given quit attempt. New strategies that have a greater population wide health benefit are needed, yet there are few effective evidence-based interventions.

Worldwide scant data exists on cytisine's efficacy compared to frontline marketed smoking cessation medications; at the exception of one RCT that demonstrated superiority with nicotine patch.

Given that no trials have compared cytisine to varenicline, the aim of this study is to conduct a world-first CONSORT-adherent, pragmatic, single-blind, noninferiority randomised controlled trial (RCT).
Short titlesmoking cessation
Effective start/end date1/01/1630/09/20


  • National Health and Medical Research Council (NHMRC) (Australia): A$1,885,813.00